American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery

Zusammenfassung

Kernaussagen

1. 1

   Metabolic and bariatric surgery (MBS) is highly effective for severe obesity, but some patients experience inadequate weight loss (non-response) or weight regain (weight recurrence).

2. 2

   Managing non-response and weight recurrence requires an individualized, multidisciplinary approach on a case-by-case basis.

3. 3

   Treatment strategies include surgical revisions (e.g., pouch revision, distalization, conversion), endoscopic therapies (e.g., transoral outlet reduction), and obesity modifying medications (OMMs).

4. 4

   Obesity modifying medications, particularly GLP-1 receptor agonists like semaglutide and dual peptide receptor agonists like tirzepatide, are major recent advances.

5. 5

   Overall data quality is limited by high loss to follow-up and outcome variability across all treatment modalities.

Geltungsbereich und Patientenzielgruppe